Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022

Published: Jul. 6, 2022 at 3:05 PM CDT

SAN DIEGO, July 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the William Blair Biotech Focus Conference 2022. The conference will take place July 12-13, 2022.

Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)
Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)(PRNewswire)

Details for this event are as follows:

  • William Blair Biotech Focus Conference 2022
    Details: Brian Lian, Ph.D., chief executive officer of Viking, will participate in a fireside chat and Viking management will participate in 1-on-1 meetings
    Conference Dates: July 12-13, 2022
    Fireside Chat Timing: Webcast available starting on Monday, July 11, 2022
    Location: The St. Regis New York

A webcast of the fireside chat may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts starting on Monday, July 11, 2022.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company's third clinical candidate is VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:

SOURCE Viking Therapeutics, Inc.

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.